Patents Assigned to IRM LLC
  • PCSK9 ANTAGONISTS
    Publication number: 20130315927
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Application
    Filed: February 10, 2012
    Publication date: November 28, 2013
    Applicants: Novartis AG, IRM LLC
    Inventors: Joshua Goldstein, Steven Bruce Cohen, Andrew Schumacher, David Langdon Yowe
  • N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS
    Publication number: 20130310375
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • METHODS OF USING ALK INHIBITORS
    Publication number: 20130296357
    Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.
    Type: Application
    Filed: February 2, 2012
    Publication date: November 7, 2013
    Applicant: IRM LLC
    Inventors: Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
  • Compounds and compositions as modulators of GPR119 activity
    Patent number: 8575168
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: November 5, 2013
    Assignee: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Gerald Lelais, John Mecom, Victor Nikulin
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8563553
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 22, 2013
    Assignees: Novartis AG, IRM LLC
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
  • ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
    Publication number: 20130274465
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 17, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • Compounds and compositions useful for the treatment of parasitic diseases
    Patent number: 8557801
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: October 15, 2013
    Assignee: IRM LLC
    Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8552002
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: October 8, 2013
    Assignees: Novartis AG, IRM LLC
    Inventors: Qiang Ding, Nathanael Schiander Gray, Bing Li, Yi Liu, Taebo Sim, Tetsuo Uno, Guobao Zhang, Carole Pissot Soldermann, Werner Breitenstein, Guido Bold, Giorgio Caravatti, Pascal Furet, Vito Guagnano, Marc Lang, Paul William Manley, Joseph Schoepfer, Carsten Spanka
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20130261108
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: October 3, 2013
    Applicant: IRM LLC
    Inventors: David C. Tully, Agnes Vidal, Daniel Mutnick, Phillip B. Alper
  • N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators
    Patent number: 8546396
    Abstract: The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: October 1, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • Compounds and compositions as kinase inhibitors
    Patent number: 8546370
    Abstract: The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS, or combinations thereof.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: October 1, 2013
    Assignee: IRM LLC
    Inventors: Barun Okram, Tetsuo Uno, Qiang Ding, Yahua Liu, Yunho Jin, Qihui Jin, Xu Wu, Jianwei Che, S. Frank Yan, Xueshi Hao
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8519129
    Abstract: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: August 27, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
  • Compounds and compositions as kinase inhibitors
    Patent number: 8518931
    Abstract: The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: August 27, 2013
    Assignee: IRM LLC
    Inventors: Tao Jiang, Pierre-Yves Michellys, Truc Ngoc Nguyen, Wei Pei, Baogen Wu, Xuefeng Zhu
  • METHODS AND COMPOSITIONS FOR TREATING CANCERS
    Publication number: 20130210771
    Abstract: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.
    Type: Application
    Filed: February 13, 2013
    Publication date: August 15, 2013
    Applicant: IRM LLC
    Inventor: Novartis AG
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
    Publication number: 20130210769
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: IRM LLC
    Inventors: Hong Liu, Xiaohui He, Dean Paul Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
  • Compounds and compositions as hedgehog pathway inhibitors
    Patent number: 8507491
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan
  • Biphenylcarboxamide derivatives as hedgehod pathway modulators
    Patent number: 8507471
    Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Christine Dierks, Markus Warmuth, Xu Wu
  • Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
    Patent number: 8507488
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Pamela A. Albaugh, Ha-Soon Choi, Gregory Chopiuk, Yi Fan, Paul Vincent Rucker, Zhicheng Wang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8501758
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: August 6, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
    Patent number: 8497075
    Abstract: The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7,25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.
    Type: Grant
    Filed: July 12, 2009
    Date of Patent: July 30, 2013
    Assignees: Novartis AG, IRM LLC, Euroscreen SA, The Scripps Research Institute
    Inventors: Birgit Baumgarten, Francois Gessier, Andreas Katopodis, Richard Knochenmuss, Rocco Falchetto, Silvio Roggo, Andreas Sailer, Klaus Seuwen, Carsten Spanka, Juan Zhang, Sebastien Hannedouche, Sophie Noel, Marie-Odile Roy, Yu Chen, Charles Y. Cho, Wei Li, Weijun Shen